Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2016-08-24

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT02877303

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ADI-PEG 20
Drug: Cytarabine

First Posted Date: 2016-08-23

Last Posted Date: 2020-03-05

Lead Sponsor: Polaris Group

Target Recruit Count: 23

Registration Number: NCT02875093

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idarubicin
Drug: Dociparstat sodium
Drug: Cytarabine

First Posted Date: 2016-08-19

Last Posted Date: 2023-09-07

Lead Sponsor: Chimerix

Target Recruit Count: 75

Registration Number: NCT02873338

Locations: 🇺🇸
Franciscan St. Francis Health, Indianapolis, Indiana, United States
🇺🇸
Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 20 locations

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase 4

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Thalidomide
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Cisplatin
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2016-08-08

Last Posted Date: 2019-06-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT02858804

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

Optimal Treatment Strategy Based on for Pediatric AML

Phase 2

Conditions: Pediatric Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Mitoxantrone
Drug: Etoposide
Procedure: Hematopoietic stem cell transplantation

First Posted Date: 2016-07-28

Last Posted Date: 2016-07-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 350

Registration Number: NCT02848183

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
🇰🇷
St. Mary Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idarubicin
Drug: Cytarabine
Drug: Indoximod Freebase
Drug: Indoximod HCL F1
Drug: Indoximod HCL F2

First Posted Date: 2016-07-18

Last Posted Date: 2020-06-04

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 54

Registration Number: NCT02835729

Locations: 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Phase 2

Recruiting

Conditions: Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Selinexor

First Posted Date: 2016-07-18

Last Posted Date: 2024-12-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 100

Registration Number: NCT02835222

Locations: 🇺🇸
Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Quizartinib
Drug: Cytarabine
Drug: Idarubicin
Drug: Daunorubicin

First Posted Date: 2016-07-15

Last Posted Date: 2021-08-19

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT02834390

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Phase 2

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Acute Leukemia of Ambiguous Lineage

Interventions: Drug: Azacitidine
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Procedure: Echocardiography
Drug: Hydrocortisone Sodium Succinate
Drug: Leucovorin
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Mercaptopurine
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Pegaspargase
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2016-07-11

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT02828358

Locations: 🇺🇸
Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States
🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States

and more 169 locations

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Phase 1

Recruiting

Conditions: Pediatric Cancer

First Posted Date: 2016-06-24

Last Posted Date: 2025-01-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 455

Registration Number: NCT02813135

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU Pellegrin, Bordeaux, France

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy